95110-10-4

Usage

Uses

Used in Pharmaceutical Industry:
(2,6-DIMETHOXY-PHENOXY)-ACETIC ACID is used as a reactant for the preparation of 1,4-benzodioxan related compounds, which are important in the development of pharmaceutical agents. These compounds exhibit a range of biological activities, including anti-inflammatory, analgesic, and antipyretic properties, making them valuable for the treatment of various medical conditions.
Used in Medicinal Chemistry Research:
(2,6-DIMETHOXY-PHENOXY)-ACETIC ACID is also used as a reactant in the synthesis of 4-phenylchroman analogues, which are of interest in the study of α1-adrenoreceptor subtypes. These analogues can help researchers understand the structure-activity relationships of these receptors and potentially lead to the development of new drugs targeting these receptors for the treatment of various diseases, such as hypertension and benign prostatic hyperplasia.

InChI:InChI=1/C10H12O5/c1-13-7-4-3-5-8(14-2)10(7)15-6-9(11)12/h3-5H,6H2,1-2H3,(H,11,12)

Upstream product

• 15267-83-1 ethyl 2-(2,6-dimethoxyphenoxy)acetate 
• 91-10-1 1,3-dimethoxy-2-hydroxy-benzene 
• 79-11-8 chloroacetic acid 

Downstream Products

• 95110-11-5 2,6-dimethoxyphenoxymethylcarboxy N-(1,4-benzodioxane-2-ylmethyl) amide 
• 86-81-7 3,4,5-trimethoxy-benzaldehyde 
• 61413-50-1 1-(4-hydroxy-3-methoxyphenyl)-2-(2,6-dimethoxyphenoxy)-propane-1,3-diol 
• 116249-92-4 threo-2-(2,6-dimethoxyphenoxy)-3-(3,4-dimethoxyphenyl)-3-hydroxypropanoic acid 
• 116249-91-3 erythro-2-(2,6-dimethoxyphenoxy)-1-(3,4-dimethoxyphenyl)-1,3-propanediol 
• 116249-91-3 threo-2-(2,6-dimethoxyphenoxy)-1-(3,4-dimethoxyphenyl)-1,3-propanediol 
• 95110-14-8 2,6-dimethoxyphenoxymethylcarboxy amide 
• 116249-88-8 methyl (2,6-dimethoxyphenoxy)acetate 
• 15267-83-1 ethyl 2-(2,6-dimethoxyphenoxy)acetate 
• 116249-89-9 (Z)-2-(2,6-dimethoxyphenoxy)-3-(3,4-dimethoxyphenyl)-2-propenoic acid 
• 116249-90-2 (E)-2-(2,6-dimethoxyphenoxy)-3-(3,4-dimethoxyphenyl)-2-propenoic acid 
• 15267-84-2 (2,6-Dimethoxy-phenoxy)-acethydroxamsaeure 
• 1093409-13-2 KNI-10260 
• 84957-90-4 Bis-[2-(2,6-dimethoxy-phenoxy)-ethyl]-amine 

Relevant academic research and scientific papers

Iridium-catalysed primary alcohol oxidation and hydrogen shuttling for the depolymerisation of lignin

Lignin is a potentially abundant renewable resource for the production of aromatic chemicals, however its selective depolymerisation is challenging. Here, we report a new catalytic system for the depolymerisation of lignin to novel, non-phenolic monoaromatic products based on the selective β-O-4 primary alcohol dehydrogenation with a Cp?Ir-bipyridonate catalyst complex under basic conditions. We show that this system is capable of promoting the depolymerisation of model compounds and isolated lignins via a sequence of selective primary alcohol dehydrogenation, retro-aldol (Cα-Cβ) bond cleavage and in situ stabilisation of the aldehyde products by transfer (de)hydrogenation to alcohols and carboxylic acids. This method was found to give good to excellent yields of cleavage products with both etherified and free-phenolic lignin model compounds and could be applied to real lignin to generate a range of novel non-phenolic monomers including diols and di-acids. We additionally show, by using the same catalyst in a convergent, one-pot procedure, that these products can be selectively channelled towards a single di-acid product, giving much simpler product mixtures as a result.

Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin

Plasmepsin (Plm) is a potential target for new antimalarial drugs, but most reported Plm inhibitors have relatively low antimalarial activities. We synthesized a series of dipeptide-type HIV protease inhibitors, which contain an allophenylnorstatine-dimethylthioproline scaffold to exhibit potent inhibitory activities against Plm II. Their activities against Plasmodium falciparum in the infected erythrocyte assay were largely different from those against the target enzyme. To improve the antimalarial activity of peptidomimetic Plm inhibitors, we attached substituents on a structure of the highly potent Plm inhibitor KNI-10006. Among the derivatives, we identified alkylamino compounds such as 44 (KNI-10283) and 47 (KNI-10538) with more than 15-fold enhanced antimalarial activity, to the sub-micromolar level, maintaining their potent Plm II inhibitory activity and low cytotoxicity. These results suggest that auxiliary substituents on a specific basic group contribute to deliver the inhibitors to the target Plm.

Synthesis and structure-activity relationships of a novel series of HIV-1 protease inhibitors encompassing ABT-378 (Lopinavir)

The HIV protease inhibitor ABT-378 (Lopinavir) has a 2,6-dimethylphenoxyacetyl group in the P-2′ position. Analogues in which this group is replaced with various substituted phenyl or heteroaryl groups were synthesized and the structure-activity relationships explored.

Synthesis of Lignin Model Compounds of the Arylglycerol β-Syringyl Ether Type

Lignin model compounds of the arylglycerol β-syringyl ether type have been prepared by the reaction of aromatic aldehydes with the α-lithiated carboxylate of (2,6-dimethoxyphenoxy)acetic acid and subsequent reduction of the 3-aryl-2-(2,6-dimethoxyphenoxy)-3-hydroxypropanoic acids formed.

Stereochemical Assignment of the threo and erythro Forms of 2-(2,6-Dimethoxyphenoxy)-1-(3,4-dimethoxyphenyl)-1,3-propanediol from X-Ray Analyses of the Synthetic Intermediates (Z)-2-(2,6-dimethoxyphenoxy)-3-(3,4-dimethoxyphenyl)-2-propenoic Acid and threo

The crystal structures of (Z)-2-(2,6-dimethoxyphenoxy)-3-(3,4-dimethoxyphenyl)-2-propenoic acid (7) and threo-2-(2,6-dimethoxyphenoxy)-3-(dimethoxyphenyl)-3-hydroxypropanoic acid (10) were determined from single-crystal X-ray diffractometer data.Starting